Related Experiment Videos
Conventional drug therapy of patients with acute myocardial infarction
Insights
Early management of myocardial infarction involves a stepwise approach. Key interventions include oxygen, nitroglycerin, and potentially heparin, with careful assessment of patient response and ECG changes guiding further treatment for acute evolving myocardial infarction.
Area of Science:
- Cardiology
- Emergency Medicine
- Internal Medicine
Background:
- There is no single standard management for myocardial infarction (MI).
- Early intervention is critical for patients presenting with chest pain.
- Guidelines offer a stepwise approach to managing suspected MI.
Purpose of the Study:
- To outline an aggressive, stepwise therapeutic approach for suspected myocardial infarction.
- To detail the use of conventional drugs, with or without thrombolytic therapy or angioplasty.
- To guide early management decisions based on patient presentation and diagnostic tests.
Main Methods:
- Initial assessment includes electrocardiogram (ECG) for prolonged chest pain at rest.
- Administration of oxygen and intravenous nitroglycerin, with careful monitoring of patient response.
- Consideration of intravenous heparin to prevent intracoronary clot redevelopment.
Main Results:
- Pain relief with nitrates/oxygen and normal ECG suggests severe angina; MI still possible.
- Persistent abnormal ECG (e.g., ST elevation) with ongoing pain indicates evolving MI.
- Morphine sulfate for refractory pain, with caution regarding hypotension/hypoventilation.
Conclusions:
- Early management of suspected myocardial infarction requires a dynamic, stepwise approach.
- Treatment decisions are guided by ECG findings, symptom response, and patient stability.
- Consideration of lidocaine for arrhythmias, atropine for bradycardia, beta-blockers, and thrombolytic therapy is essential.
Abstract:
In medicine and in cardiology one must be aware that there is no "standard" management for any condition. However, some guidelines can be offered for the management of myocardial infarction in the early stages. The following can be considered an aggressive but stepwise approach to therapy of patients with suspected myocardial infarction using conventional drugs with or without thrombolytic therapy or coronary angioplasty. Any patient presenting with prolonged chest pain occurring at rest should have an electrocardiogram. If the ECG is abnormal, an evolving myocardial infarction can be suspected. In this setting, oxygen should be administered if the patient is dyspneic, cyanotic, or has rales in the chest, intravenous nitroglycerin should be given, and the patient's response should be assessed. Caution should be observed at this point if the patient is sweating or hypotensive. Administration of a vasodilator in a dehydrated patient may drop the blood pressure further. If pain is relieved and the ECG returns to normal, the working diagnosis is severe angina. However, acute myocardial infarction should not be dismissed. A strong case for the use of intravenous heparin can be made to prevent the redevelopment of intracoronary clot inasmuch as thrombosis probably occurs in most patients presenting with unstable and severe angina, as it most surely does in patients with an evolving acute myocardial infarction. If nitrates and oxygen relieve chest pain but the ECG remains abnormal, for example, ST segment elevation, the diagnosis of acute evolving myocardial infarction must be considered and intravenous nitrates should be continued. If the patient has no relief of pain from nitrates and oxygen and the ECG remains abnormal, morphine sulfate should be administered intravenously in sufficient dosage to relieve the chest pain but not produce hypotension or hypoventilation. Once the diagnosis of myocardial infarction has been made, some would begin administering intravenous lidocaine as prophylaxis against the ventricular arrhythmias commonly encountered in the earlier stages of myocardial infarction. It has not been my practice to use prophylactic lidocaine, but I believe it is prudent to have a low threshold for the use of this drug in patients with frequent PVCs, especially if they are multifocal. If the patient exhibits symptomatic bradycardia or heart block, a trial with intravenous atropine is warranted. Additionally, while all of this is going on, one should contemplate using beta-blockers if there is good indication, and thrombolytic therapy if there are no contraindications to its use.